For the quarter ending 2025-09-30, DYN had $88,583K increase in cash & cash equivalents over the period. -$91,174K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -108,040 | -226,219 |
| Depreciation and amortization expense | - | 1,005 |
| Stock-based compensation expense | 11,082 | 23,543 |
| Depreciation and amortization expense | 523 | 1,005 |
| Non-cash lease expense | 96 | 32 |
| Non-cash interest expense | 60 | 2 |
| Accretion of premium on marketable securities | -368 | -1,079 |
| Loss (gain) on sale of marketable securities | 0 | -14 |
| Loss (gain) on disposal of property and equipment | 0 | -95 |
| Prepaid expenses and other current assets | -389 | -2,795 |
| Other non-current assets | 12,991 | - |
| Accounts payable and other liabilities | 18,470 | -756 |
| Net cash used in operating activities | -90,779 | -200,596 |
| Purchases of property and equipment | 395 | 1,041 |
| Advance payment for long-lead equipment | 18,790 | - |
| Purchases of marketable securities | 46,920 | 106,903 |
| Maturities of marketable securities | 28,139 | 107,708 |
| Sales of marketable securities | 1 | 8,468 |
| Net cash used in investing activities | -37,965 | 8,232 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 215,803 | 0 |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 0 | 140,653 |
| Proceeds from exercise of stock options | 2,073 | 2,560 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | 0 | 98,802 |
| Payment of debt issuance costs | 549 | - |
| Net cash provided by financing activities | 217,327 | 242,015 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 88,583 | 49,651 |
| Cash and cash equivalents at beginning of period | 437,391 | - |
| Cash and cash equivalents at end of period | 575,625 | - |
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)